In this study, an integrated pharmacology strategy employing serum pharmacochemistry, network pharmacological analysis, and experimental validation was conducted to illustrate the therapeutic mechanism of XPF in treating CHD with depression (Figure 1). Here, ERCC4 is linked to depressive disorder.